MARKET

TPTX

TPTX

Turning Point Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

86.69
+3.17
+3.80%
After Hours: 86.69 0 0.00% 16:00 09/25 EDT
OPEN
82.69
PREV CLOSE
83.52
HIGH
86.78
LOW
82.69
VOLUME
171.63K
TURNOVER
--
52 WEEK HIGH
89.30
52 WEEK LOW
31.30
MARKET CAP
3.66B
P/E (TTM)
-23.2856
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and
GlobeNewswire · 4d ago
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in question and answer
GlobeNewswire · 09/01 14:00
Turning Point Therapeutics Announces Scientific Advisory Board
Turning Point Therapeutics Announces Scientific Advisory Board SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation
Benzinga · 08/31 13:00
FDA grants fast-track designation for Repotrectinib to Turning Point
The Food and Drug Administration (FDA) granted Turning Point Therapeutics (TPTX +2.0%) a third Fast-Track designation to its lead drug candidate, repotrect
Seeking Alpha - Article · 08/24 14:29
Turning Point's repotrectinib Fast Track'd in U.S. for certain solid tumors
The Food and Drug Administration ((FDA)) granted Turning Point Therapeutics ([[TPTX]] +2.0%) a third Fast-Track designation to its lead drug candidate, repotrectinib for treatment of patients with advanced solid tumors that
Seekingalpha · 08/24 14:29
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors
SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted a third Fast-Track designation to its lead
GlobeNewswire · 08/24 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TPTX. Analyze the recent business situations of Turning Point Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TPTX stock price target is 85.44 with a high estimate of 100.00 and a low estimate of 77.00.
EPS
Institutional Holdings
Institutions: 200
Institutional Holdings: 37.27M
% Owned: 88.38%
Shares Outstanding: 42.17M
TypeInstitutionsShares
Increased
62
6.46M
New
59
2.09M
Decreased
29
1.10M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.18%
Pharmaceuticals & Medical Research
+1.35%
Key Executives
Chairman/Director
Sheila Gujrathi
President/Chief Executive Officer/Director
Athena Countouriotis
Chief Financial Officer/Executive Vice President
Yi Larson
Executive Vice President/Chief Scientific Officer
Siegfried Reich
Executive Vice President/General Counsel/Secretary
Annette North
Executive Vice President
Mohammad Hirmand
Vice President - Finance
Brian Baker
Vice President/Director of Human Resources
Heather Adams
Independent Director
Jacob Chacko
Independent Director
Carol Gallagher
Independent Director
Simeon George
Independent Director
Carl Gordon
Independent Director
Patrick Machado
Independent Director
Garry Nicholson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TPTX
Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies. Its tyrosine kinase inhibitors (TKIs) pipeline targets numerous genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The Company has developed a macrocycle platform enabling to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. The Company’s lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Turning Point Therapeutics Inc stock information, including NASDAQ:TPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TPTX stock methods without spending real money on the virtual paper trading platform.